Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Pfeiffer P, Sørbye H, Ehrsson H, Fokstuen T, Mortensen JP, Baltesgard L, Tveit KM, Øgreid D, Starkhammar H, Wallin I, Qvortrup C, Glimelius B. Pfeiffer P, et al. Among authors: qvortrup c. Ann Oncol. 2006 Feb;17(2):252-8. doi: 10.1093/annonc/mdj060. Epub 2005 Nov 15. Ann Oncol. 2006. PMID: 16291583 Free article. Clinical Trial.
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Qvortrup C, Yilmaz M, Ogreid D, Berglund A, Balteskard L, Ploen J, Fokstuen T, Starkhammar H, Sørbye H, Tveit K, Pfeiffer P. Qvortrup C, et al. Ann Oncol. 2008 Jun;19(6):1154-9. doi: 10.1093/annonc/mdn002. Epub 2008 Feb 14. Ann Oncol. 2008. PMID: 18281265 Free article. Clinical Trial.
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen FO, Pfeiffer P. Qvortrup C, et al. Ann Oncol. 2010 Jan;21(1):87-91. doi: 10.1093/annonc/mdp272. Epub 2009 Jul 21. Ann Oncol. 2010. PMID: 19622596 Free article. Clinical Trial.
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.
Glimelius B, Lahn M, Gawande S, Cleverly A, Darstein C, Musib L, Liu Y, Spindler KL, Frödin JE, Berglund A, Byström P, Qvortrup C, Jakobsen A, Pfeiffer P. Glimelius B, et al. Among authors: qvortrup c. Ann Oncol. 2010 May;21(5):1020-6. doi: 10.1093/annonc/mdp521. Epub 2009 Nov 9. Ann Oncol. 2010. PMID: 19901015 Free article. Clinical Trial.
83 results